Compare OPAL & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPAL | ICCC |
|---|---|---|
| Founded | 1998 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.8M | 64.0M |
| IPO Year | 2021 | 1995 |
| Metric | OPAL | ICCC |
|---|---|---|
| Price | $2.20 | $8.26 |
| Analyst Decision | Sell | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $2.72 | N/A |
| AVG Volume (30 Days) | ★ 157.0K | 25.7K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 650.00 | 53.85 |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $348,975,000.00 | $26,493,169.00 |
| Revenue This Year | $12.84 | N/A |
| Revenue Next Year | $9.11 | N/A |
| P/E Ratio | $15.60 | ★ N/A |
| Revenue Growth | 16.34 | ★ 51.64 |
| 52 Week Low | $1.65 | $4.52 |
| 52 Week High | $4.08 | $8.46 |
| Indicator | OPAL | ICCC |
|---|---|---|
| Relative Strength Index (RSI) | 38.44 | 70.36 |
| Support Level | $2.03 | $5.78 |
| Resistance Level | $2.50 | N/A |
| Average True Range (ATR) | 0.11 | 0.35 |
| MACD | -0.03 | 0.09 |
| Stochastic Oscillator | 0.00 | 90.61 |
OPAL Fuels Inc is a fully integrated, nationwide leader in the production and distribution of low-carbon intensity renewable natural gas. The company is also engaged in the marketing and distribution of RNG to heavy-duty trucking and other hard-to-de-carbonize industrial sectors. The company designs, develops, constructs, operates, and services Fueling Stations for trucking fleets across the country that use natural gas to displace diesel as their transportation fuel. The company derives revenue from the sale of Renewable Power, design, development, construction, and service of Fueling Stations, and sales of RNG produced by OPAL and third parties as pipeline-quality natural gas.
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.